25 XP   0   0   10

CellaVision AB
Buy, Hold or Sell?

Let's analyse Cellavision together

PenkeI guess you are interested in CellaVision AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of CellaVision AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about CellaVision AB

I send you an email if I find something interesting about CellaVision AB.

Quick analysis of Cellavision (30 sec.)










What can you expect buying and holding a share of Cellavision? (30 sec.)

How much money do you get?

How much money do you get?
kr0.41
When do you have the money?
1 year
How often do you get paid?
80.0%

What is your share worth?

Current worth
kr30.02
Expected worth in 1 year
kr33.13
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
kr7.62
Return On Investment
3.5%

For what price can you sell your share?

Current Price per Share
kr220.50
Expected price per share
kr213.50 - kr272.50
How sure are you?
50%

1. Valuation of Cellavision (5 min.)




Live pricePrice per Share (EOD)

kr220.50

Intrinsic Value Per Share

kr42.59 - kr135.99

Total Value Per Share

kr72.61 - kr166.01

2. Growth of Cellavision (5 min.)




Is Cellavision growing?

Current yearPrevious yearGrowGrow %
How rich?$65.4m$55.2m$6.8m11.0%

How much money is Cellavision making?

Current yearPrevious yearGrowGrow %
Making money$2.9m$2.7m$273.6k9.2%
Net Profit Margin18.7%18.1%--

How much money comes from the company's main activities?

3. Financial Health of Cellavision (5 min.)




4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  


Richest
#156 / 334

Most Revenue
#164 / 334

Most Profit
#79 / 334

What can you expect buying and holding a share of Cellavision? (5 min.)

Welcome investor! Cellavision's management wants to use your money to grow the business. In return you get a share of Cellavision.

What can you expect buying and holding a share of Cellavision?

First you should know what it really means to hold a share of Cellavision. And how you can make/lose money.

Speculation

The Price per Share of Cellavision is kr220.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cellavision.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cellavision, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr30.02. Based on the TTM, the Book Value Change Per Share is kr0.78 per quarter. Based on the YOY, the Book Value Change Per Share is kr1.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr1.13 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cellavision.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps0.190.1%0.120.1%0.110.1%0.110.0%0.080.0%
Usd Book Value Change Per Share0.150.1%0.070.0%0.090.0%0.080.0%0.060.0%
Usd Dividend Per Share0.000.0%0.100.0%0.180.1%0.110.0%0.100.0%
Usd Total Gains Per Share0.150.1%0.170.1%0.280.1%0.190.1%0.160.1%
Usd Price Per Share19.38-16.78-25.92-26.36-17.71-
Price to Earnings Ratio25.08-37.33-72.79-70.48-55.86-
Price-to-Total Gains Ratio132.86-116.93-100.83-182.98-245.74-
Price to Book Ratio7.06-6.44-11.26-15.21-13.11-
Price-to-Total Gains Ratio132.86-116.93-100.83-182.98-245.74-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share20.1537
Number of shares49
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.100.11
Usd Book Value Change Per Share0.070.08
Usd Total Gains Per Share0.170.19
Gains per Quarter (49 shares)8.539.37
Gains per Year (49 shares)34.1137.48
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1201424211627
2402858433264
36042926448101
481561268664138
51017016010780175
61218419412996212
714198228150112249
8161112262172128286
9181126296193144323
10202140330215160360

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%61.00.035.063.5%
Book Value Change Per Share3.01.00.075.0%11.01.00.091.7%18.02.00.090.0%33.07.00.082.5%60.036.00.062.5%
Dividend per Share2.00.02.050.0%10.00.02.083.3%15.00.05.075.0%32.00.08.080.0%38.00.058.039.6%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%69.027.00.071.9%

Fundamentals of Cellavision

About CellaVision AB

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, designs to automate and simplify the process of performing blood and body fluid differentials; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Proficiency Software, a web-based software designed to help laboratory managers assess, monitor, and promote staff competency in cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. Further, the company offers reagents to identify cell and tissue morphology, parasites, and bacteria in diagnosing various diseases; and instruments, including RAL SmearBox, RAL Stainbox, and RAL Stainer. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.

Fundamental data was last updated by Penke on 2024-04-20 20:02:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of CellaVision AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cellavision earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Cellavision to the Medical Devices industry mean.
  • A Net Profit Margin of 25.1% means that kr0.25 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of CellaVision AB:

  • The MRQ is 25.1%. The company is making a huge profit. +2
  • The TTM is 18.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ25.1%TTM18.7%+6.4%
TTM18.7%YOY18.1%+0.6%
TTM18.7%5Y19.9%-1.2%
5Y19.9%10Y20.3%-0.4%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ25.1%-12.4%+37.5%
TTM18.7%-20.4%+39.1%
YOY18.1%-14.4%+32.5%
5Y19.9%-21.3%+41.2%
10Y20.3%-25.0%+45.3%
1.1.2. Return on Assets

Shows how efficient Cellavision is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cellavision to the Medical Devices industry mean.
  • 5.4% Return on Assets means that Cellavision generated kr0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of CellaVision AB:

  • The MRQ is 5.4%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 3.6%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ5.4%TTM3.6%+1.8%
TTM3.6%YOY3.4%+0.1%
TTM3.6%5Y4.0%-0.4%
5Y4.0%10Y5.0%-1.0%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4%-4.1%+9.5%
TTM3.6%-4.7%+8.3%
YOY3.4%-4.6%+8.0%
5Y4.0%-4.0%+8.0%
10Y5.0%-5.2%+10.2%
1.1.3. Return on Equity

Shows how efficient Cellavision is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cellavision to the Medical Devices industry mean.
  • 7.0% Return on Equity means Cellavision generated kr0.07 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of CellaVision AB:

  • The MRQ is 7.0%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 4.8%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ7.0%TTM4.8%+2.3%
TTM4.8%YOY4.9%-0.2%
TTM4.8%5Y5.8%-1.1%
5Y5.8%10Y6.7%-0.8%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ7.0%-4.2%+11.2%
TTM4.8%-5.8%+10.6%
YOY4.9%-5.5%+10.4%
5Y5.8%-6.3%+12.1%
10Y6.7%-7.1%+13.8%

1.2. Operating Efficiency of CellaVision AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cellavision is operating .

  • Measures how much profit Cellavision makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cellavision to the Medical Devices industry mean.
  • An Operating Margin of 31.2% means the company generated kr0.31  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of CellaVision AB:

  • The MRQ is 31.2%. The company is operating very efficient. +2
  • The TTM is 24.1%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ31.2%TTM24.1%+7.1%
TTM24.1%YOY24.2%-0.2%
TTM24.1%5Y26.0%-2.0%
5Y26.0%10Y19.6%+6.4%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ31.2%-24.3%+55.5%
TTM24.1%-16.4%+40.5%
YOY24.2%-14.0%+38.2%
5Y26.0%-20.4%+46.4%
10Y19.6%-24.8%+44.4%
1.2.2. Operating Ratio

Measures how efficient Cellavision is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 0.69 means that the operating costs are kr0.69 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of CellaVision AB:

  • The MRQ is 0.688. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.759. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.688TTM0.759-0.071
TTM0.759YOY0.758+0.002
TTM0.7595Y0.911-0.151
5Y0.91110Y0.754+0.157
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6881.456-0.768
TTM0.7591.439-0.680
YOY0.7581.431-0.673
5Y0.9111.436-0.525
10Y0.7541.374-0.620

1.3. Liquidity of CellaVision AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cellavision is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 3.07 means the company has kr3.07 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of CellaVision AB:

  • The MRQ is 3.068. The company is very able to pay all its short-term debts. +2
  • The TTM is 2.873. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ3.068TTM2.873+0.196
TTM2.873YOY2.972-0.099
TTM2.8735Y2.969-0.097
5Y2.96910Y2.486+0.483
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0682.693+0.375
TTM2.8732.697+0.176
YOY2.9723.504-0.532
5Y2.9693.617-0.648
10Y2.4863.499-1.013
1.3.2. Quick Ratio

Measures if Cellavision is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cellavision to the Medical Devices industry mean.
  • A Quick Ratio of 2.01 means the company can pay off kr2.01 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of CellaVision AB:

  • The MRQ is 2.010. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.697. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.010TTM1.697+0.313
TTM1.697YOY1.723-0.026
TTM1.6975Y1.637+0.060
5Y1.63710Y1.371+0.266
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0101.516+0.494
TTM1.6971.658+0.039
YOY1.7232.142-0.419
5Y1.6372.307-0.670
10Y1.3712.370-0.999

1.4. Solvency of CellaVision AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cellavision assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cellavision to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.23 means that Cellavision assets are financed with 22.9% credit (debt) and the remaining percentage (100% - 22.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of CellaVision AB:

  • The MRQ is 0.229. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.249. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.229TTM0.249-0.020
TTM0.249YOY0.298-0.049
TTM0.2495Y0.317-0.068
5Y0.31710Y0.262+0.055
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2290.402-0.173
TTM0.2490.389-0.140
YOY0.2980.335-0.037
5Y0.3170.442-0.125
10Y0.2620.461-0.199
1.4.2. Debt to Equity Ratio

Measures if Cellavision is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cellavision to the Medical Devices industry mean.
  • A Debt to Equity ratio of 29.6% means that company has kr0.30 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of CellaVision AB:

  • The MRQ is 0.296. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.332. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.296TTM0.332-0.036
TTM0.332YOY0.425-0.093
TTM0.3325Y0.478-0.146
5Y0.47810Y0.370+0.108
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2960.559-0.263
TTM0.3320.560-0.228
YOY0.4250.479-0.054
5Y0.4780.614-0.136
10Y0.3700.674-0.304

2. Market Valuation of CellaVision AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Cellavision generates.

  • Above 15 is considered overpriced but always compare Cellavision to the Medical Devices industry mean.
  • A PE ratio of 25.08 means the investor is paying kr25.08 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of CellaVision AB:

  • The EOD is 26.088. Based on the earnings, the company is overpriced. -1
  • The MRQ is 25.082. Based on the earnings, the company is overpriced. -1
  • The TTM is 37.333. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD26.088MRQ25.082+1.006
MRQ25.082TTM37.333-12.251
TTM37.333YOY72.786-35.453
TTM37.3335Y70.480-33.147
5Y70.48010Y55.858+14.621
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD26.088-1.021+27.109
MRQ25.082-1.704+26.786
TTM37.333-2.081+39.414
YOY72.786-2.980+75.766
5Y70.480-2.379+72.859
10Y55.858-1.726+57.584
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of CellaVision AB:

  • The EOD is 24.834. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 23.877. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is -11.008. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD24.834MRQ23.877+0.957
MRQ23.877TTM-11.008+34.885
TTM-11.008YOY171.844-182.853
TTM-11.0085Y47.093-58.102
5Y47.09310Y36.669+10.425
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD24.834-0.981+25.815
MRQ23.877-1.578+25.455
TTM-11.008-2.973-8.035
YOY171.844-6.179+178.023
5Y47.093-4.928+52.021
10Y36.669-5.060+41.729
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cellavision is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 7.06 means the investor is paying kr7.06 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of CellaVision AB:

  • The EOD is 7.346. Based on the equity, the company is overpriced. -1
  • The MRQ is 7.063. Based on the equity, the company is overpriced. -1
  • The TTM is 6.437. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD7.346MRQ7.063+0.283
MRQ7.063TTM6.437+0.626
TTM6.437YOY11.260-4.823
TTM6.4375Y15.209-8.772
5Y15.20910Y13.108+2.101
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD7.3461.930+5.416
MRQ7.0632.372+4.691
TTM6.4372.444+3.993
YOY11.2603.205+8.055
5Y15.2093.893+11.316
10Y13.1084.245+8.863
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of CellaVision AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.5960.779+105%1.031+55%0.892+79%0.612+161%
Book Value Per Share--30.01728.487+5%25.354+18%21.049+43%14.634+105%
Current Ratio--3.0682.873+7%2.972+3%2.969+3%2.486+23%
Debt To Asset Ratio--0.2290.249-8%0.298-23%0.317-28%0.262-13%
Debt To Equity Ratio--0.2960.332-11%0.425-30%0.478-38%0.370-20%
Dividend Per Share---1.125-100%2.000-100%1.200-100%1.122-100%
Eps--2.1131.366+55%1.240+70%1.179+79%0.905+133%
Free Cash Flow Per Share--2.2201.152+93%0.711+212%1.021+117%1.379+61%
Free Cash Flow To Equity Per Share--1.7810.135+1217%-0.236+113%0.521+242%0.979+82%
Gross Profit Margin--0.328-0.186+157%-0.343+205%0.459-29%0.729-55%
Intrinsic Value_10Y_max--135.988--------
Intrinsic Value_10Y_min--42.595--------
Intrinsic Value_1Y_max--6.701--------
Intrinsic Value_1Y_min--3.686--------
Intrinsic Value_3Y_max--25.412--------
Intrinsic Value_3Y_min--11.645--------
Intrinsic Value_5Y_max--50.487--------
Intrinsic Value_5Y_min--20.167--------
Market Cap5259255750.000+4%5059616804.0004378723661.850+16%6764920952.125-25%6879676424.410-26%4630570767.830+9%
Net Profit Margin--0.2510.187+34%0.181+39%0.199+26%0.203+24%
Operating Margin--0.3120.241+30%0.242+29%0.260+20%0.196+59%
Operating Ratio--0.6880.759-9%0.758-9%0.911-24%0.754-9%
Pb Ratio7.346+4%7.0636.437+10%11.260-37%15.209-54%13.108-46%
Pe Ratio26.088+4%25.08237.333-33%72.786-66%70.480-64%55.858-55%
Price Per Share220.500+4%212.000183.550+15%283.625-25%288.430-26%193.759+9%
Price To Free Cash Flow Ratio24.834+4%23.877-11.008+146%171.844-86%47.093-49%36.669-35%
Price To Total Gains Ratio138.188+4%132.861116.930+14%100.829+32%182.983-27%245.736-46%
Quick Ratio--2.0101.697+18%1.723+17%1.637+23%1.371+47%
Return On Assets--0.0540.036+51%0.034+58%0.040+36%0.050+9%
Return On Equity--0.0700.048+48%0.049+43%0.058+21%0.067+6%
Total Gains Per Share--1.5961.904-16%3.031-47%2.092-24%1.734-8%
Usd Book Value--65477954.60062111829.700+5%55273030.350+18%45889431.070+43%31947126.545+105%
Usd Book Value Change Per Share--0.1460.071+105%0.094+55%0.082+79%0.056+161%
Usd Book Value Per Share--2.7442.604+5%2.317+18%1.924+43%1.338+105%
Usd Dividend Per Share---0.103-100%0.183-100%0.110-100%0.103-100%
Usd Eps--0.1930.125+55%0.113+70%0.108+79%0.083+133%
Usd Free Cash Flow--4842006.4002512563.150+93%1550349.650+212%2225471.180+118%3013133.530+61%
Usd Free Cash Flow Per Share--0.2030.105+93%0.065+212%0.093+117%0.126+61%
Usd Free Cash Flow To Equity Per Share--0.1630.012+1217%-0.022+113%0.048+242%0.089+82%
Usd Market Cap480695975.550+4%462448975.886400215342.693+16%618313775.024-25%628802425.191-26%423234168.180+9%
Usd Price Per Share20.154+4%19.37716.776+15%25.923-25%26.363-26%17.710+9%
Usd Profit--4609393.4002977560.650+55%2703931.900+70%2571232.810+79%1976824.335+133%
Usd Revenue--18337764.80015476122.200+18%14608919.000+26%12866368.860+43%9621828.810+91%
Usd Total Gains Per Share--0.1460.174-16%0.277-47%0.191-24%0.158-8%
 EOD+4 -4MRQTTM+29 -7YOY+29 -75Y+27 -910Y+29 -7

3.2. Fundamental Score

Let's check the fundamental score of CellaVision AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1526.088
Price to Book Ratio (EOD)Between0-17.346
Net Profit Margin (MRQ)Greater than00.251
Operating Margin (MRQ)Greater than00.312
Quick Ratio (MRQ)Greater than12.010
Current Ratio (MRQ)Greater than13.068
Debt to Asset Ratio (MRQ)Less than10.229
Debt to Equity Ratio (MRQ)Less than10.296
Return on Equity (MRQ)Greater than0.150.070
Return on Assets (MRQ)Greater than0.050.054
Total7/10 (70.0%)

3.3. Technical Score

Let's check the technical score of CellaVision AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.423
Ma 20Greater thanMa 50225.700
Ma 50Greater thanMa 100235.470
Ma 100Greater thanMa 200220.729
OpenGreater thanClose230.500
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets928,712
Total Liabilities212,323
Total Stockholder Equity716,389
 As reported
Total Liabilities 212,323
Total Stockholder Equity+ 716,389
Total Assets = 928,712

Assets

Total Assets928,712
Total Current Assets365,590
Long-term Assets563,122
Total Current Assets
Cash And Cash Equivalents 121,645
Net Receivables 117,907
Inventory 126,038
Total Current Assets  (as reported)365,590
Total Current Assets  (calculated)365,590
+/-0
Long-term Assets
Property Plant Equipment 125,502
Goodwill 123,780
Intangible Assets 309,443
Long-term Assets Other 1
Long-term Assets  (as reported)563,122
Long-term Assets  (calculated)558,726
+/- 4,396

Liabilities & Shareholders' Equity

Total Current Liabilities119,154
Long-term Liabilities93,169
Total Stockholder Equity716,389
Total Current Liabilities
Short-term Debt 36,039
Short Long Term Debt 36,039
Accounts payable 32,534
Other Current Liabilities 50,581
Total Current Liabilities  (as reported)119,154
Total Current Liabilities  (calculated)155,193
+/- 36,039
Long-term Liabilities
Long term Debt 28,664
Long-term Liabilities  (as reported)93,169
Long-term Liabilities  (calculated)28,664
+/- 64,505
Total Stockholder Equity
Common Stock3,578
Retained Earnings 684,560
Accumulated Other Comprehensive Income 17,451
Other Stockholders Equity 10,800
Total Stockholder Equity (as reported)716,389
Total Stockholder Equity (calculated)716,389
+/-0
Other
Capital Stock3,578
Cash and Short Term Investments 121,645
Common Stock Shares Outstanding 23,866
Liabilities and Stockholders Equity 928,712
Net Debt -56,942
Net Invested Capital 781,092
Net Working Capital 246,437
Property Plant and Equipment Gross 216,446
Short Long Term Debt Total 64,703



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-31
> Total Assets 
39,235
111,285
100,031
84,885
73,264
65,751
51,270
115,346
97,837
83,631
68,181
73,687
58,855
50,048
42,020
30,530
56,818
51,695
41,574
45,116
35,531
40,520
36,341
46,240
39,936
41,030
39,353
41,329
38,592
33,969
47,264
44,120
50,495
57,447
58,626
96,473
82,191
79,344
90,772
113,352
96,582
110,323
122,095
162,501
152,911
163,922
156,532
178,728
169,606
161,920
181,359
178,556
176,041
166,293
171,274
188,573
185,997
171,482
184,570
202,249
212,461
182,644
208,451
220,428
233,586
217,046
233,350
256,445
279,282
266,156
280,365
300,597
312,221
307,372
329,036
372,782
418,867
417,792
437,483
641,709
677,591
664,860
666,587
668,025
707,200
726,228
746,983
825,212
849,476
843,334
860,496
891,748
897,071
898,192
894,442
928,712
928,712894,442898,192897,071891,748860,496843,334849,476825,212746,983726,228707,200668,025666,587664,860677,591641,709437,483417,792418,867372,782329,036307,372312,221300,597280,365266,156279,282256,445233,350217,046233,586220,428208,451182,644212,461202,249184,570171,482185,997188,573171,274166,293176,041178,556181,359161,920169,606178,728156,532163,922152,911162,501122,095110,32396,582113,35290,77279,34482,19196,47358,62657,44750,49544,12047,26433,96938,59241,32939,35341,03039,93646,24036,34140,52035,53145,11641,57451,69556,81830,53042,02050,04858,85573,68768,18183,63197,837115,34651,27065,75173,26484,885100,031111,28539,235
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
216,426
233,466
214,450
225,290
239,435
244,350
238,530
257,806
294,570
307,801
306,282
326,257
265,251
283,676
286,283
288,750
298,066
327,126
313,667
329,187
364,719
381,912
357,602
367,930
377,144
362,676
338,167
333,688
365,590
365,590333,688338,167362,676377,144367,930357,602381,912364,719329,187313,667327,126298,066288,750286,283283,676265,251326,257306,282307,801294,570257,806238,530244,350239,435225,290214,450233,466216,4260000000000000000000000000000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
132,454
148,022
123,415
129,028
154,546
152,072
142,822
164,422
169,057
214,346
190,196
218,185
102,312
99,305
115,492
95,357
102,262
112,832
91,271
111,538
130,286
147,006
110,033
116,201
108,053
93,074
34,897
78,832
121,645
121,64578,83234,89793,074108,053116,201110,033147,006130,286111,53891,271112,832102,26295,357115,49299,305102,312218,185190,196214,346169,057164,422142,822152,072154,546129,028123,415148,022132,4540000000000000000000000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
2,148
0
0
0
7,208
0
0
0
4,651
0
0
0
5,216
0
0
0
9,322
0
0
0
10,964
0
0
0
13,692
0
14,011
19,973
14,075
18,469
23,604
25,151
38,048
21,835
20,633
29,891
30,585
18,101
24,546
35,231
40,826
28,825
37,183
32,781
32,358
25,484
27,214
39,624
49,304
41,346
33,867
43,643
49,185
30,809
43,133
44,328
69,462
42,583
39,416
43,313
43,439
46,353
51,472
60,710
43,796
53,982
59,167
67,708
51,401
64,700
63,132
65,876
85,835
53,804
66,782
57,931
104,640
117,786
100,966
107,828
108,691
130,952
130,672
114,809
89,736
89,723
99,047
91,800
97,630
117,571
146,338
115,375
117,907
117,907115,375146,338117,57197,63091,80099,04789,72389,736114,809130,672130,952108,691107,828100,966117,786104,64057,93166,78253,80485,83565,87663,13264,70051,40167,70859,16753,98243,79660,71051,47246,35343,43943,31339,41642,58369,46244,32843,13330,80949,18543,64333,86741,34649,30439,62427,21425,48432,35832,78137,18328,82540,82635,23124,54618,10130,58529,89120,63321,83538,04825,15123,60418,46914,07519,97314,011013,69200010,9640009,3220005,2160004,6510007,2080002,148000
       Other Current Assets 
0
0
0
550
4,869
6,061
16,385
1,500
13,007
11,844
11,964
1,338
12,228
15,417
14,043
1,033
13,264
17,578
17,214
836
14,529
22,199
26,559
786
23,572
23,061
19,518
809
28,222
0
0
1,111
0
0
0
607
0
0
0
800
0
0
0
1,172
0
0
0
2,340
0
0
0
1,730
0
0
0
1,887
0
0
0
2,293
0
0
0
2,521
0
0
0
3,901
0
0
0
4,734
0
0
0
791
0
0
0
602
0
359
266
610
0
0
0
119,345
119,013
124,314
29,768
872
31,067
33,422
26,620
1
126,62033,42231,06787229,768124,314119,013119,34500061026635906020007910004,7340003,9010002,5210002,2930001,8870001,7300002,3400001,1720008000006070001,1110028,22280919,51823,06123,57278626,55922,19914,52983617,21417,57813,2641,03314,04315,41712,2281,33811,96411,84413,0071,50016,3856,0614,869550000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
111,066
111,510
111,226
376,458
393,915
378,576
377,839
369,959
380,075
412,562
417,796
460,493
467,564
485,730
492,566
514,604
534,394
560,026
560,754
563,122
563,122560,754560,026534,394514,604492,566485,730467,564460,493417,796412,562380,075369,959377,839378,576393,915376,458111,226111,510111,0660000000000000000000000000000000000000000000000000000000000000000000000000000
       Property Plant Equipment 
1,379
1,496
1,366
1,758
1,879
1,968
2,186
3,771
3,720
3,321
3,034
3,956
5,046
4,113
3,684
3,827
3,948
3,276
2,936
2,398
2,203
1,827
1,451
1,302
1,018
729
1,670
1,373
1,260
1,482
1,830
1,257
1,126
1,803
2,395
2,824
2,774
2,632
2,460
2,270
2,022
1,869
1,729
1,592
1,558
1,803
1,660
2,015
2,177
2,085
2,343
2,693
3,237
3,101
2,809
3,195
3,058
3,109
3,474
3,203
3,305
2,829
3,014
2,652
2,463
2,702
2,445
3,270
4,236
4,859
4,584
4,814
4,707
4,350
4,376
6,815
36,667
34,410
32,556
54,494
54,307
51,668
49,260
47,427
48,540
47,968
46,726
80,326
79,340
83,317
84,746
110,034
119,087
125,537
124,750
125,502
125,502124,750125,537119,087110,03484,74683,31779,34080,32646,72647,96848,54047,42749,26051,66854,30754,49432,55634,41036,6676,8154,3764,3504,7074,8144,5844,8594,2363,2702,4452,7022,4632,6523,0142,8293,3053,2033,4743,1093,0583,1952,8093,1013,2372,6932,3432,0852,1772,0151,6601,8031,5581,5921,7291,8692,0222,2702,4602,6322,7742,8242,3951,8031,1261,2571,8301,4821,2601,3731,6707291,0181,3021,4511,8272,2032,3982,9363,2763,9483,8273,6844,1135,0463,9563,0343,3213,7203,7712,1861,9681,8791,7581,3661,4961,379
       Goodwill 
0
0
0
0
0
0
8,244
7,823
7,169
5,943
5,716
5,060
4,341
3,639
3,087
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
115,121
0
0
0
111,972
0
0
0
114,085
0
0
0
124,141
125,788
131,541
128,201
123,780
123,780128,201131,541125,788124,141000114,085000111,972000115,12100000000000000000000000000000000000000000000000000000000000000003,0873,6394,3415,0605,7165,9437,1697,8238,244000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,245
2,240
2,616
2,617
4,645
2,627
3,200
3,579
3,590
3,600
3,612
22,295
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000022,2953,6123,6003,5903,5793,2002,6274,6452,6172,6162,2402,24500000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
22,250
24,284
26,386
0
0
0
8,244
7,823
7,169
5,943
5,716
5,060
4,341
3,639
3,087
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,911
0
0
9,222
10,893
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
53,731
58,519
0
0
900
70,809
73,500
75,058
184,547
315,959
304,475
306,037
300,883
309,525
342,776
349,185
244,075
365,975
379,601
384,046
275,089
284,554
297,955
302,827
309,443
309,443302,827297,955284,554275,089384,046379,601365,975244,075349,185342,776309,525300,883306,037304,475315,959184,54775,05873,50070,8099000058,51953,731000000000000000000000000000000000000010,8939,222002,911000000000000003,0873,6394,3415,0605,7165,9437,1697,8238,24400026,38624,28422,250
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
111,066
111,510
111,226
2
393,915
0
0
1
0
0
0
22,007
22,249
22,812
23,774
5,340
4,965
4,993
4,976
1
14,9764,9934,9655,34023,77422,81222,24922,007000100393,9152111,226111,510111,0660000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
14,758
23,663
16,000
18,213
16,614
23,751
23,183
32,742
31,628
29,400
23,641
25,023
22,244
22,949
22,589
22,461
23,967
25,949
20,288
26,968
21,663
29,762
30,527
19,679
18,290
19,686
20,368
23,596
22,014
20,540
29,955
24,048
28,963
34,528
32,120
50,488
34,586
30,856
34,558
38,553
26,914
34,670
44,792
49,079
38,574
48,745
39,014
52,661
39,818
38,699
52,339
53,644
53,201
55,737
51,314
56,057
47,886
36,670
44,031
50,953
51,977
38,449
40,747
36,910
39,505
44,866
46,943
50,270
46,292
47,251
53,915
59,746
58,336
69,384
70,196
82,407
103,347
107,866
110,527
293,336
294,695
266,154
253,150
238,408
244,000
254,365
246,499
281,932
264,502
256,889
254,592
250,120
232,782
238,521
216,549
212,323
212,323216,549238,521232,782250,120254,592256,889264,502281,932246,499254,365244,000238,408253,150266,154294,695293,336110,527107,866103,34782,40770,19669,38458,33659,74653,91547,25146,29250,27046,94344,86639,50536,91040,74738,44951,97750,95344,03136,67047,88656,05751,31455,73753,20153,64452,33938,69939,81852,66139,01448,74538,57449,07944,79234,67026,91438,55334,55830,85634,58650,48832,12034,52828,96324,04829,95520,54022,01423,59620,36819,68618,29019,67930,52729,76221,66326,96820,28825,94923,96722,46122,58922,94922,24425,02323,64129,40031,62832,74223,18323,75116,61418,21316,00023,66314,758
   > Total Current Liabilities 
3,884
12,650
4,849
11,908
10,153
13,139
12,419
23,141
21,951
19,417
13,498
10,839
7,721
8,134
7,399
8,632
9,779
11,422
5,566
15,948
10,603
28,642
29,307
18,439
17,070
18,086
18,688
23,596
22,015
20,540
29,955
24,048
28,963
34,528
32,120
50,488
34,586
30,856
34,558
38,553
26,914
34,670
44,792
49,079
38,574
48,745
39,014
52,661
39,818
38,699
52,339
53,644
53,201
55,737
51,314
56,057
47,886
36,670
44,031
50,953
51,977
38,449
40,747
36,910
39,505
44,866
46,943
50,270
46,292
47,251
53,915
51,126
49,433
60,182
59,749
71,890
69,245
74,406
78,502
125,863
128,152
111,220
109,325
104,145
113,957
121,503
120,648
134,500
121,485
120,155
125,446
133,092
118,180
130,856
120,508
119,154
119,154120,508130,856118,180133,092125,446120,155121,485134,500120,648121,503113,957104,145109,325111,220128,152125,86378,50274,40669,24571,89059,74960,18249,43351,12653,91547,25146,29250,27046,94344,86639,50536,91040,74738,44951,97750,95344,03136,67047,88656,05751,31455,73753,20153,64452,33938,69939,81852,66139,01448,74538,57449,07944,79234,67026,91438,55334,55830,85634,58650,48832,12034,52828,96324,04829,95520,54022,01523,59618,68818,08617,07018,43929,30728,64210,60315,9485,56611,4229,7798,6327,3998,1347,72110,83913,49819,41721,95123,14112,41913,13910,15311,9084,84912,6503,884
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
41,374
45,065
49,371
0
52,192
0
0
0
0
0
0
40,809
89,575
89,396
90,641
42,131
82,078
89,903
91,549
36,039
36,03991,54989,90382,07842,13190,64189,39689,57540,80900000052,192049,37145,06541,3740000000000000000000000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
41,374
45,065
49,371
50,766
52,192
47,632
47,333
0
38,389
0
49,562
0
48,773
89,396
90,641
42,131
82,078
89,903
91,549
36,039
36,03991,54989,90382,07842,13190,64189,39648,773049,562038,389047,33347,63252,19250,76649,37145,06541,3740000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
3,312
0
0
0
5,900
0
0
0
3,363
0
0
0
2,048
0
0
0
4,021
0
0
0
3,147
0
0
0
7,761
0
6,900
7,495
6,084
7,174
8,212
9,256
17,224
16,193
9,399
9,182
13,791
8,342
9,722
12,606
11,140
9,101
13,665
11,740
16,549
13,264
11,724
16,834
16,458
12,014
17,581
16,464
10,641
13,857
9,037
15,284
12,297
12,815
8,839
10,690
7,338
14,330
16,698
14,851
16,451
15,588
16,938
16,712
21,490
17,304
20,088
19,642
26,753
19,494
20,897
20,375
21,716
25,511
19,450
21,232
20,865
24,829
28,149
30,159
44,861
31,910
30,759
34,805
47,864
36,102
40,953
27,099
32,534
32,53427,09940,95336,10247,86434,80530,75931,91044,86130,15928,14924,82920,86521,23219,45025,51121,71620,37520,89719,49426,75319,64220,08817,30421,49016,71216,93815,58816,45114,85116,69814,3307,33810,6908,83912,81512,29715,2849,03713,85710,64116,46417,58112,01416,45816,83411,72413,26416,54911,74013,6659,10111,14012,6069,7228,34213,7919,1829,39916,19317,2249,2568,2127,1746,0847,4956,90007,7610003,1470004,0210002,0480003,3630005,9000003,312000
       Other Current Liabilities 
3,884
12,650
4,849
3,597
10,153
13,139
12,419
6,879
21,951
19,417
13,498
6,560
7,721
8,134
7,399
5,099
9,779
11,422
5,566
5,030
10,603
28,642
29,307
6,499
17,070
18,086
18,688
8,677
22,015
9,855
9,325
10,511
10,040
10,428
11,830
12,463
8,528
10,195
9,213
11,101
13,977
15,229
14,127
17,104
15,677
16,907
14,503
20,393
19,342
20,917
20,103
22,914
24,804
24,163
19,296
25,438
21,511
27,633
28,747
38,656
39,162
29,610
30,057
29,572
25,175
28,168
32,092
33,819
30,704
30,313
37,203
29,636
32,129
40,094
40,107
18,359
43,243
47,003
51,333
15,710
50,449
44,138
40,760
10,393
40,279
45,233
51,880
46,625
51,266
50,600
51,603
43,097
41,190
47,702
1,860
50,581
50,5811,86047,70241,19043,09751,60350,60051,26646,62551,88045,23340,27910,39340,76044,13850,44915,71051,33347,00343,24318,35940,10740,09432,12929,63637,20330,31330,70433,81932,09228,16825,17529,57230,05729,61039,16238,65628,74727,63321,51125,43819,29624,16324,80422,91420,10320,91719,34220,39314,50316,90715,67717,10414,12715,22913,97711,1019,21310,1958,52812,46311,83010,42810,04010,5119,3259,85522,0158,67718,68818,08617,0706,49929,30728,64210,6035,0305,56611,4229,7795,0997,3998,1347,7216,56013,49819,41721,9516,87912,41913,13910,1533,5974,84912,6503,884
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
34,102
33,460
32,025
167,473
166,543
154,934
143,825
134,263
130,043
134,917
125,851
147,432
143,017
136,734
129,146
117,028
114,602
107,665
96,041
93,169
93,16996,041107,665114,602117,028129,146136,734143,017147,432125,851134,917130,043134,263143,825154,934166,543167,47332,02533,46034,1020000000000000000000000000000000000000000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
86,904
81,371
83,528
75,462
95,845
87,170
78,335
69,430
60,364
52,758
43,155
32,711
0
032,71143,15552,75860,36469,43078,33587,17095,84575,46283,52881,37186,90400000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
34,724
39,335
44,607
47,875
53,731
58,519
61,865
63,654
66,918
0
0
0
75,459
0
0
0
94,269
0
0
0
126,275
0
0
0
162,709
0
0
0
0
0000162,709000126,27500094,26900075,45900066,91863,65461,86558,51953,73147,87544,60739,33534,7240000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
24,478
87,622
84,030
66,673
56,650
41,999
28,087
82,604
66,209
54,231
44,540
48,664
36,611
27,099
19,431
8,069
32,851
25,746
21,286
18,148
13,868
10,758
5,814
26,561
21,646
21,344
18,985
17,733
16,578
13,429
17,309
20,072
21,532
22,919
26,506
45,985
47,605
48,488
56,214
74,799
69,668
75,653
77,303
113,422
114,337
115,177
117,518
126,067
129,788
123,221
129,020
124,912
122,840
110,556
119,960
132,516
138,111
134,812
140,539
151,296
160,484
144,195
167,704
183,518
194,081
172,180
186,407
206,175
232,990
218,905
226,450
240,851
253,885
237,988
258,840
290,375
315,520
309,926
326,956
348,373
382,896
398,706
413,437
429,617
463,200
471,863
500,484
543,280
584,974
586,445
605,904
641,628
664,289
659,671
677,893
716,389
716,389677,893659,671664,289641,628605,904586,445584,974543,280500,484471,863463,200429,617413,437398,706382,896348,373326,956309,926315,520290,375258,840237,988253,885240,851226,450218,905232,990206,175186,407172,180194,081183,518167,704144,195160,484151,296140,539134,812138,111132,516119,960110,556122,840124,912129,020123,221129,788126,067117,518115,177114,337113,42277,30375,65369,66874,79956,21448,48847,60545,98526,50622,91921,53220,07217,30913,42916,57817,73318,98521,34421,64626,5615,81410,75813,86818,14821,28625,74632,8518,06919,43127,09936,61148,66444,54054,23166,20982,60428,08741,99956,65066,67384,03087,62224,478
   Common Stock
24,478
87,622
84,030
748
56,650
41,999
28,087
1,930
66,209
54,231
44,540
2,026
36,611
27,099
19,431
2,026
32,851
25,746
21,286
3,023
13,868
10,758
5,814
3,537
21,646
21,344
18,985
3,577
16,578
13,429
17,309
3,577
21,532
22,919
26,506
3,577
47,605
48,488
56,214
3,577
69,668
75,653
77,303
3,578
114,337
115,177
117,518
3,578
129,788
123,221
129,020
3,578
122,840
110,556
119,960
3,578
138,111
134,812
140,539
3,578
160,484
144,195
167,704
3,578
194,081
172,180
186,407
3,578
232,990
218,905
226,450
3,578
253,885
237,988
258,840
3,578
315,520
309,926
326,956
3,578
382,896
398,706
413,437
3,578
463,200
471,863
500,484
3,578
584,974
586,445
605,904
3,578
664,289
659,671
677,893
3,578
3,578677,893659,671664,2893,578605,904586,445584,9743,578500,484471,863463,2003,578413,437398,706382,8963,578326,956309,926315,5203,578258,840237,988253,8853,578226,450218,905232,9903,578186,407172,180194,0813,578167,704144,195160,4843,578140,539134,812138,1113,578119,960110,556122,8403,578129,020123,221129,7883,578117,518115,177114,3373,57877,30375,65369,6683,57756,21448,48847,6053,57726,50622,91921,5323,57717,30913,42916,5783,57718,98521,34421,6463,5375,81410,75813,8683,02321,28625,74632,8512,02619,43127,09936,6112,02644,54054,23166,2091,93028,08741,99956,65074884,03087,62224,478
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,451
17,45100000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,693
0
0
0
2,423
0
0
0
-964
0
0
0
-6,360
382,896
398,706
413,437
-14,596
463,200
471,863
500,484
2,417
584,974
586,445
605,904
30,133
664,289
659,671
677,893
10,800
10,800677,893659,671664,28930,133605,904586,445584,9742,417500,484471,863463,200-14,596413,437398,706382,896-6,360000-9640002,4230001,6930000000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue677,292
Cost of Revenue-214,251
Gross Profit463,041463,041
 
Operating Income (+$)
Gross Profit463,041
Operating Expense-295,989
Operating Income167,052167,052
 
Operating Expense (+$)
Research Development83,333
Selling General Administrative76,032
Selling And Marketing Expenses136,624
Operating Expense295,989295,989
 
Net Interest Income (+$)
Interest Income777
Interest Expense-3,260
Other Finance Cost-7,561
Net Interest Income5,078
 
Pretax Income (+$)
Operating Income167,052
Net Interest Income5,078
Other Non-Operating Income Expenses0
Income Before Tax (EBT)164,222169,882
EBIT - interestExpense = 163,792
164,222
133,569
Interest Expense3,260
Earnings Before Interest and Taxes (EBIT)167,052167,482
Earnings Before Interest and Taxes (EBITDA)199,815
 
After tax Income (+$)
Income Before Tax164,222
Tax Provision-28,770
Net Income From Continuing Ops112,175135,452
Net Income130,309
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses510,240
Total Other Income/Expenses Net-2,830-5,078
 

Technical Analysis of Cellavision
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cellavision. The general trend of Cellavision is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cellavision's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of CellaVision AB.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 244.00 < 271.17 < 272.50.

The bearish price targets are: 215.00 > 215.00 > 213.50.

Tweet this
CellaVision AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of CellaVision AB. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

CellaVision AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of CellaVision AB. The current macd is -0.56860233.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cellavision price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cellavision. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cellavision price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
CellaVision AB Daily Moving Average Convergence/Divergence (MACD) ChartCellaVision AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of CellaVision AB. The current adx is 17.44.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Cellavision shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
CellaVision AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of CellaVision AB. The current sar is 245.50.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
CellaVision AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of CellaVision AB. The current rsi is 44.42. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
CellaVision AB Daily Relative Strength Index (RSI) ChartCellaVision AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of CellaVision AB. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cellavision price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
CellaVision AB Daily Stochastic Oscillator ChartCellaVision AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of CellaVision AB. The current cci is -32.97904912.

CellaVision AB Daily Commodity Channel Index (CCI) ChartCellaVision AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of CellaVision AB. The current cmo is -15.84317699.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
CellaVision AB Daily Chande Momentum Oscillator (CMO) ChartCellaVision AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of CellaVision AB. The current willr is -75.75757576.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cellavision is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
CellaVision AB Daily Williams %R ChartCellaVision AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of CellaVision AB.

CellaVision AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of CellaVision AB. The current atr is 10.37.

CellaVision AB Daily Average True Range (ATR) ChartCellaVision AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of CellaVision AB. The current obv is 65,680.

CellaVision AB Daily On-Balance Volume (OBV) ChartCellaVision AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of CellaVision AB. The current mfi is 58.10.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
CellaVision AB Daily Money Flow Index (MFI) ChartCellaVision AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for CellaVision AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-07ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-12MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

CellaVision AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of CellaVision AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.423
Ma 20Greater thanMa 50225.700
Ma 50Greater thanMa 100235.470
Ma 100Greater thanMa 200220.729
OpenGreater thanClose230.500
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cellavision with someone you think should read this too:
  • Are you bullish or bearish on Cellavision? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cellavision? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about CellaVision AB

I send you an email if I find something interesting about CellaVision AB.


Comments

How you think about this?

Leave a comment

Stay informed about CellaVision AB.

Receive notifications about CellaVision AB in your mailbox!